Dr Zuraira Mujahid, Dr Romesa Kaleem, Dr Hamza Faiz
Background: Since past some decades, multi-drug opposing (MDR) reappearance of polymixin remission, particularly in serious patients, with gram-negative infections, Polymixin was less toxic than before. Objective: The objective of above subject is to sort and highlight the effectiveness of intravenous polymixin (Colistin) against multidrug resistant organisms in children with sepsis. Material and Methods: Total 195 patients who were culture positive (urine, blood, tracheal aspirate, CSF fluid) for MDR organisms were included. Polymyxin at dose of 5 mg/kg/day, in 3 divided doses was started and continued for 21 days. Success of the medication was assessed according to microorganism growth in con¬trol cultures, together with clinical and radiographic improvements after 48 hrs of medication. Descriptive statistics were calculated. Stratification was done and post stratification chi-square test was applied. P-value ≤ 0.05 was taken as significant. This case series study was conducted at Children Hospital, Lahore from January, 2018 To July, 2018. Results: Efficacy was among 90.3% patients. There were 78.5% male and 21.5% female patients. Mean age was 6.19±2.5 years. Mean weight after 48 hours of treatment was 2.36±0.68 kg. Mean therapy duration was 6.62±3.91 days. Mean therapy dose was 69647.69±95789.41 IU. Mean hospital stay was 11.71±5.84 days. Most common source of the micro-organism was blood. X–rays of 52.3% were found improved after 48 hours of treatment. Conclusion: Effectiveness with 90.3%, polymyxin was well tolerated and better option for the management of MDR-GNB infections. Keywords: Multidrug Resistant Organisms, Efficacy, Sepsis, Intravenous Polymixin (Colistin).